Lundbeck Completes Early Patient Enrollment in Phase 3 Trial for Rare Neurodegenerative Disease MSA
Key Insights
Lundbeck announced ahead-of-schedule completion of patient randomization in the global Phase 3 MASCOT trial evaluating amlenetug for multiple system atrophy (search) (MSA (search)), a rare and fatal neurodegenerative disorder with no approved treatments.
Amlenetug is a novel monoclonal antibody targeting α-synuclein (search) protein that showed promising results in Phase 2 trials and could become the first-in-class therapy for MSA (search).
The early enrollment completion reflects strong engagement from the global MSA (search) community and underscores the urgent unmet medical need for this devastating disease.
Lundbeck has announced the completion of patient randomization ahead of schedule in its global Phase 3 MASCOT trial evaluating amlenetug, an investigational monoclonal antibody for multiple system atrophy (search) (MSA (search)), a rare and fatal neurodegenerative disorder with no currently approved treatments.
The multicenter trial is ongoing across North America, Europe, Asia, and Australia to evaluate amlenetug's potential to slow clinical disease progression in MSA (search) patients. The early completion of randomization underscores the significant unmet medical need and strong collaboration with patient and investigator communities.
Novel Therapeutic Approach
Amlenetug is designed to target the α-synuclein (search) protein in the brain and inhibit its spread to nearby brain cells. By addressing a key underlying cause of MSA (search), the therapy holds potential to become a first-in-class treatment for this rare disorder. The monoclonal antibody recognizes and binds to all major forms of extracellular α-synuclein, intended to prevent uptake and inhibit seeding of aggregation.
"Completing randomization of a global Phase 3 trial in MSA (search) is a significant achievement for the field," said Professor Günter Höglinger, Lead Investigator of the MASCOT trial. "Advancing the development of a potential treatment for this underserved disease addresses a critical unmet need for people living with MSA."
The compound demonstrated promising results in a Phase 2 trial, suggesting potential to slow disease progression in MSA (search) patients.
Addressing Critical Unmet Need
MSA (search) is a rapidly progressing rare condition that causes damage to nerve cells in the brain. Symptoms typically start between 55 and 60 years of age, with a typical time to death of 8.6 years after symptom onset. The disease is seriously debilitating and places a high burden on patients, with symptoms including muscle control problems similar to Parkinson's disease, urinary incontinence, frequent falling, and unintelligible speech occurring within 3 years of disease onset.
"With no currently available treatments to slow the clinical progression of MSA (search), the urgency for innovation is exceptionally high," said Johan Luthman, Executive Vice President and Head of Research and Development at Lundbeck. "Successfully randomizing the last patient into the trial sets us on a strong trajectory to hopefully bring a much-needed treatment to people living with this devastating disease."
Trial Design and Timeline
The MASCOT trial comprises two parts: a double-blind period where participants are randomized to receive either high or low doses of amlenetug, or placebo for 72 weeks, followed by an open-label extension period where all participants are offered treatment with amlenetug. The therapy is delivered as an intravenous infusion every four weeks.
Amlenetug has received Orphan Drug Designation in the EU, Japan, and the U.S., as well as Fast Track designation in the U.S. and SAKIGAKE designation in Japan. Headline results are anticipated in Q3 2027, with expected launch in Q1 2029.
With randomization now complete, participants will progress through the double-blind treatment period followed by the optional open-label extension as planned.